COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study

被引：0
|
作者：
Allsup, David [1 ,2 ]
Howard, Dena [3 ]
Emmerson, Jake [3 ]
Hockaday, Anna [3 ]
Rawstron, Andy [4 ]
Oughton, Jamie B. [3 ]
Bloor, Adrian [5 ]
Phillips, David [3 ]
Nathwani, Amit [6 ]
Paneesha, Shankara [7 ]
Turner, Deborah [8 ]
Munir, Talha [9 ]
Hillmen, Peter [9 ]
机构：
[1] Hull Univ Teaching Hosp, Haematol, Kingston Upon Hull, Yorks, England
[2] Hull York Med Sch, Ctr Atherothrombosis & Metab Dis, Kingston Upon Hull, N Humberside, England
[3] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England
[4] St James Univ Hosp, Leeds, W Yorkshire, England
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Coll London Hosp, London, England
[7] Birmingham Heartlands Hosp, Birmingham, W Midlands, England
[8] Torbay Dist Hosp, Torquay, England
[9] St James Univ Hosp, St James Inst Oncol, Leeds, W Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 03期
关键词：
chronic lymphocytic leukaemia; chemotherapy; clinical trial; monoclonal antibody; minimal residual disease; FLUDARABINE; CYCLOPHOSPHAMIDE; CHLORAMBUCIL; RITUXIMAB;
D O I：
10.1111/bjh.17526
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：646 / 650
页数：5
相关论文
共 50 条
  • [41] for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (vol 385, pg 1873, 2015)
    Hillmen, P.
    Robak, T.
    Janssens, A.
    LANCET, 2016, 387 (10026): : E24 - E24
  • [42] Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
    Blum, Kristie A.
    Advani, Anjani
    Fernandez, Louis
    Van Der Jagt, Richard
    Brandwein, Joseph
    Kambhampati, Suman
    Kassis, Jeannine
    Davis, Melanie
    Bonfils, Claire
    Dubay, Marja
    Dumouchel, Julie
    Drouin, Michel
    Lucas, David M.
    Martell, Robert E.
    Byrd, John C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (04) : 507 - 514
  • [43] First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomised Study of Zanubrutinib versus Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
    Hillmen, Peter
    Eichhorst, Barbara
    Brown, Jennifer R.
    Lamanna, Nicole
    O'Brien, Susan
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Salmi, Tommi
    Ji, Meng
    Yecies, Jessica
    Wu, Kenneth
    Novotny, William
    Huang, Jane
    Jurczak, Wojciech
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 92 - 93
  • [44] Phase II study on starting with reduced dose of regorafenib for metastatic colorectal cancer after standard chemotherapy
    Ota, Hirofumi
    Kagawa, Yoshinori
    Ohta, Katsuya
    Miyazaki, Susumu
    Hamabe, Atsushi
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Yamamoto, Hirofumi
    Doki, Yuichiro
    Mori, Masaki
    CANCER SCIENCE, 2018, 109 : 307 - 307
  • [45] Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Samoilova, Olga
    Novak, Jan
    Ben-Yehuda, Dina
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Hsu, Emily
    Lih, Chih-Jian
    Zhou, Cathy
    Clow, Fong
    James, Danelle F.
    Styles, Lori
    Flinn, Ian W.
    LANCET ONCOLOGY, 2019, 20 (01): : 43 - 56
  • [46] Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma
    Guan, Z
    Wang, Y
    Maoleekoonpairoj, S
    Chen, Z
    Kim, WS
    Ratanatharathorn, V
    Reece, WHH
    Kim, TW
    Lehnert, M
    BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1865 - 1869
  • [47] Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma
    Z Guan
    Y Wang
    S Maoleekoonpairoj
    Z Chen
    W S Kim
    V Ratanatharathorn
    W H H Reece
    T W Kim
    M Lehnert
    British Journal of Cancer, 2003, 89 : 1865 - 1869
  • [48] RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
    Danilov, A.
    Yimer, H.
    Boxer, M.
    Di Bella, N.
    Babu, S.
    Li, J.
    Mun, Y.
    Skettino, S.
    Sharman, J.
    HAEMATOLOGICA, 2017, 102 : 71 - 71
  • [49] Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results Fro a Phase II Study Of The Czech Leukemia Study Group For Life
    Doubek, Michael
    Brychtova, Yvona
    Panovska, Anna
    Trizuljak, Jakub
    Sebejova, Ludmila
    Stehlikova, Olga
    Chovancova, Jana
    Malcikova, Jitka
    Smardova, Jana
    Plevova, Karla
    Volfova, Pavlina
    Trbusek, Martin
    Mraz, Marek
    Majercakova, Denisa
    Obrtlikova, Petra
    Karban, Josef
    Smolej, Lukas
    Lindtnerova, Michaela
    Oltova, Alexandra
    Jelinkova, Eva
    Pospisilova, Sarka
    Mayer, Jiri
    BLOOD, 2013, 122 (21)
  • [50] Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report
    Miklos, Udvardy
    Strugov, Vladimir
    Lewerin, Catharina
    Grosicki, Sebastian
    Mazur, Grzegorz
    Steurer, Michael
    Montillo, Marco
    Kryachok, Irina
    Middeke, Jan M.
    Rekhtman, Grygoriy
    Stefanelli, Tommaso
    Vincent, Ghislaine
    Govindaraju, Sameera
    Osterborg, Anders
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : 689 - 693
12345